Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines

Vaccine

Volumn 33, Issue , 2015, Pages D60-D65

  Pilishvili, Tamara ^a   Bennett, Nancy M ^b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Pneumococcal vaccine; Policy; Prevention

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; VACCINE;

ADULT; DRUG EFFICACY; HEALTH CARE POLICY; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; VACCINATION; ADVISORY COMMITTEE; AGED; IMMUNOLOGY; MICROBIOLOGY; PNEUMONIA, PNEUMOCOCCAL; UNITED STATES; VERY ELDERLY;

ADULT; ADVISORY COMMITTEES; AGED; AGED, 80 AND OVER; HEALTH POLICY; HUMANS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; UNITED STATES; VACCINATION; VACCINES, CONJUGATE;

EID: 84951567318     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.102     Document Type: Review

References (43)

1. Lu P.J., Nuorti J.P. Pneumococcal polysaccharide vaccination among adults aged 65 years and older, U.S., 1989-2008. Am J Prev Med 2010, 39(Oct (4)):287-295.
2. Williams W.W., Lu P.-J., O'Halloran A., et al. Noninfluenza vaccination coverage among adults-United States, 2012. MMWR Morb Mortal Wkly Rep 2014, 63(5):95-102.
3. Fedson D.S. Preventing non bacteremic pneumococcal pneumonia in older adults. Hum Vaccin Immunother 2014, 10(5):1322-1330.
4. Pilishvili T., Lexau C., Farley M.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
5. Moore M.R., Link-Gelles R., Schaffner W., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015, (Feb (3)). 10.1016/s1473-3099(1014)71081-71083.
6. Simonsen L., Taylor R.J., Schuck-Paim C., Lustig R., Haber M., Klugman K.P. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med 2014, 2(5):387-394.
7. Tomczyk S., Bennett N.M., Stoecker C., et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014, 63(Sep (37)):822-825.
8. Bonten M.J.M., Huijts S.M., Bolkenbaas M., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015, 372(12):1114-1125.
9. Hak E., Grobbee D.E., Sanders E.A., et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008, 66(Oct (9)):378-383.
10. Centers for Disease Control & Prevention Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61(Oct (40)):816-819.
11. Jackson L.A., Gurtman A., van Cleeff M., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013, 31(35):3577-3584.
12. Jackson L.A., Gurtman A., Rice K., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013, 31(35):3585-3593.
13. Feikin D.R., Elie C.M., Goetz M.B., et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2002, 20(Nov (3-4)):545-553.
14. Lesprit P., Pedrono G., Molina J.M., et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007, 21(Nov (18)):2425-2434.
15. Penaranda M., Payeras A., Cambra A., Mila J., Riera M. Majorcan pneumococcal study G. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010, 24(May (8)):1226-1228.
16. Crum-Cianflone N.F., Huppler Hullsiek K., Roediger M., et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010, 202(Oct (7)):1114-1125.
17. Glesby M.J., Watson W., Brinson C., et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis 2014, 212(Nov (1)):18-27.
18. Bonten M., Bolkenbaas M., Huijts S., et al. Community-acquired pneumonia immunisation trial in adults (CAPITA). Pneumonia 2014, 3(Mar (9-13)):95.
19. French N., Gordon S.B., Mwalukomo T., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362(Mar (9)):812-822.
20. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, 1:CD000422.
21. Simberkoff M.S., Cross A.P., Al-Ibrahim M., et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a veterans administration cooperative study. N Engl J Med 1986, 315(21):1318-1327.
22. Smit P., Oberholzer D., Hayden-Smith S., Koornhof H.J., Hilleman M.R. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977, 238(24):2613-2616.
23. Kaufman P. Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide; results of a six year study. Arch Intern Med 1947, 79(5):518-531.
24. Ortqvist A., Grepe A., Julander I., Kalin M. Bacteremic pneumococcal pneumonia in Sweden: clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias. Scand J Infect Dis 1988, 20(2):163-171.
25. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180(1):48-58.
26. Maruyama T., Gabazza E.C., Morser J., et al. Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir Med 2010, 104(4):584-592.
27. Ochoa-Gondar O., Vila-Corcoles A., Rodriguez-Blanco T., et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014, 58(Apr (7)):909-917.
28. Said M.A., Johnson H.L., Nonyane B.A., et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE 2013, 8(4):e60273.
29. Organization W.H. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008, 83:373-384.
30. Moore M.R., Link-Gelles R., Schaffner W., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015, 15(Mar (3)):301-309.
31. Jackson L.A., Gurtman A., van Cleeff M., et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013, 31(35):3594-3602.
32. Miernyk K.M., Butler J.C., Bulkow L.R., et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55-70 years of age. Clin Infect Dis 2009, 49(July (2)):241-248.
33. Goldblatt D., Southern J., Andrews N., et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009, 49(Nov (9)):1318-1325.
34. Greenberg R.N., Gurtman A., Frenck R.W., et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 2014, 32(20):2364-2374.
35. Blackwell D., Lucas J., Clarke T. Summary health statistics for U.S. adults: National Health Interview Survey, 2012. National Center for Health Statistics. Vital Health Stat 2014, 10(260). 〈http://www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf〉.
36. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(May (18)):1737-1746.
37. Pilishvili T., Gierke R., Kim L., Stoecker C. Potential public health impact of 13-valent pneumococcal conjugate vaccine use among adults 65 years of age or older. Paper presented at: IDWeek 2014.
38. Williams W.W., Lu P.-J., O'Halloran A., et al. Vaccination coverage among adults, excluding influenza vaccination-United States, 2013. MMWR Morb Mortal Wkly Rep 2015, 64(4):95-102.
39. MMWR Influenza and pneumococcal vaccination coverage among persons aged greater than or equal to 65 years-United States, 2004-2005. MMWR: Morb Mortal Wkly Rep 2006, 55(39):1065-1068.
40. Centers for Disease Control & Prevention Active Bacterial Core surveillance (ABCs), methodology-data collection and forms 2013, Centers for Disease Control & Prevention, 〈http://www.cdc.gov/abcs/methodology/data-collect-forms.html〉 (accessed December 5, 2013).
41. Drijkoningen J.J.C., Rohde G.G.U. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 2014, 20(Suppl 5 (0)):45-51.
42. Pride M.W., Huijts S.M., Wu K., et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol 2012, 19(8):1131-1141.
43. Bewick T., Sheppard C., Greenwood S., et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012, 67(6):540-545.